PCSK9 inhibitor valuation: A science‐based review of the two recent models

por Baum, Seth J., Cannon, Christopher P.
Publicado 2018

Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?

por Sabouret, Pierre, Angoulvant, Denis, Cannon, Christopher P, Banach, Maciej
Publicado 2022

Gender Differences in Aspirin use Among Adults With Coronary Heart Disease in the United States

por Opotowsky, Alexander R., McWilliams, J. Michael, Cannon, Christopher P.
Publicado 2007

A remote hypertension management program clinical algorithm

por Nichols, Hunter, Cannon, Christopher P., Scirica, Benjamin M., Fisher, Naomi D. L.
Publicado 2022

Distal Femur Allograft Prosthetic Composite Reconstruction for Short Proximal Femur Segments following Tumor Resection

por Moon, Bryan S., Gilbert, Nathan F., Cannon, Christopher P., Lin, Patrick P., Lewis, Valerae O.
Publicado 2013

Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes

por Byrne, Connie E, Fitzgerald, Anthony, Cannon, Christopher P, Fitzgerald, Desmond J, Shields, Denis C
Publicado 2004

Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review

por Leiva, Orly, AbdelHameid, Duaa, Connors, Jean M., Cannon, Christopher P., Bhatt, Deepak L.
Publicado 2021

The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?

por Gargiulo, Giuseppe, Cannon, Christopher P, Gibson, Charles Michael, Lopes, Renato D, Vranckx, Pascal, Valgimigli, Marco
Publicado 2020

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo

por Cannon, Christopher P, Chen, Cong, Curtis, Sean P, Viscusi, John, Ahmed, Tuli, DiBattiste, Peter M
Publicado 2008

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER...

por Ference, Brian A, Cannon, Christopher P, Landmesser, Ulf, Lüscher, Thomas F, Catapano, Alberico L, Ray, Kausik K
Publicado 2018

Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies

por Khan, Irfan, Peterson, Eric D., Cannon, Christopher P., Sedita, Lauren E., Edelberg, Jay M., Ray, Kausik K.
Publicado 2020

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials

por Ginsberg, Henry N., Rosenson, Robert S., Hovingh, G. Kees, Letierce, Alexia, Samuel, Rita, Poulouin, Yann, Cannon, Christopher P.
Publicado 2021

Early and Chronic Dipeptidyl‐Peptidase‐IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of th...

por Sharma, Abhinav, Cannon, Christopher P., White, William B., Liu, Yuyin, Bakris, George L., Cushman, William C., Zannad, Faiez
Publicado 2018

Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis

por Behrouzi, Bahar, Bhatt, Deepak L., Cannon, Christopher P., Vardeny, Orly, Lee, Douglas S., Solomon, Scott D., Udell, Jacob A.
Publicado 2022

Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub‐analysis of ODYSSEY COMBO II

por Leiter, Lawrence A., Zamorano, José Luis, Bujas‐Bobanovic, Maja, Louie, Michael J., Lecorps, Guillaume, Cannon, Christopher P., Handelsman, Yehuda
Publicado 2017

Heart failure with mid‐range ejection fraction: characterization of patients from the PINNACLE Registry®

por Ibrahim, Nasrien E., Song, Yang, Cannon, Christopher P., Doros, Gheorghe, Russo, Patricia, Ponirakis, Angelo, Alexanian, Claire, Januzzi, James L.
Publicado 2019

Alteration of medical therapy in patients with heart failure relative to change in symptom severity

por Ibrahim, Nasrien E., Song, Yang, Cannon, Christopher P., Doros, Gheorghe, Russo, Patricia, Ponirakis, Angelo, Alexanian, Claire, Januzzi, James L.
Publicado 2019

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO...

por Cannon, Christopher P., Cariou, Bertrand, Blom, Dirk, McKenney, James M., Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh, Colhoun, Helen M.
Publicado 2015

Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial

por Bellavia, Andrea, Wallentin, Lars, Orsini, Nicola, James, Stefan K, Cannon, Christopher P, Himmelmann, Anders, Sundström, Johan, Renlund, Henrik, Lytsy, Per
Publicado 2017

Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Tri...

por Sharma, Abhinav, Vaduganathan, Muthiah, Ferreira, João Pedro, Liu, Yuyin, Bakris, George L., Cannon, Christopher P., White, William B., Zannad, Faiez
Publicado 2020